NMDAR Agonist Therapy for Autoimmune Encephalitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune-induced glutamatergic receptor dysfunction, particularly anti-NMDAR encephalitis, are inadequate in alleviating psychiatric manifestations and often lead to relapses, with limited options for managing motor and cognitive symptoms.
Innovation Solution
The use of NMDAR agonists, such as glycine, D-Serine, or D-cycloserine, along with inhibitors of glycine transport and D-amino acid oxidase, to enhance NMDAR-mediated neurotransmission and mitigate the severity of autoimmune encephalitis symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for autoimmune encephalitis are used, then immunological response is addressed, but psychiatric and cognitive symptoms are inadequately alleviated and relapses occur
Solution Approach 1:
The treatment approach is segmented into two distinct components: (1) immunotherapy to address the underlying autoimmune response, and (2) NMDAR agonist therapy to directly treat the glutamatergic receptor dysfunction. This segmentation allows each treatment to target its specific mechanism without interfering with the other, thereby comprehensively addressing both immunological and neurological symptoms
Solution Approach 2:
NMDAR agonists serve as an intermediary substance that mediates between the autoimmune damage and functional recovery. These agonists bind to and activate NMDAR receptors that have been dysfunctional due to autoimmune attack, thereby restoring normal glutamatergic neurotransmission and preventing psychiatric manifestations
2Ease of operation
If NMDAR agonists are administered to enhance neurotransmission, then cognitive and motor symptoms improve, but potential over-stimulation of glutamatergic receptors may occur
Solution Approach 1:
The patent employs partial agonists or sub-maximal doses of full agonists to achieve sufficient NMDAR activation for therapeutic effect without causing excessive stimulation. This partial action principle allows the treatment to provide beneficial cognitive and motor improvements while staying below the threshold for harmful over-stimulation
Solution Approach 2:
The treatment regimen includes monitoring of clinical response and adjustment of NMDAR agonist dosing based on patient tolerance and symptom improvement. This feedback mechanism ensures that the dosage remains in the optimal therapeutic window, preventing both under-treatment and over-stimulation of receptors
Data Source
AI summary
This invention provides a method of enhancing NMDAR-mediated neurotransmission in a disease associated with NMDAR antibody production, said method comprising administering an NMDAR agonist, an alanine-serine-cysteine transporter inhibitor, a D-amino acid oxidase inhibitor, a glycine transport inhibitor or a combination thereof to said subject. This invention also provides a method of mitigating the severity of, mitigating the pathogenesis of, lowering the incidence of or treating a disease associated with NMDAR antibody production, said method comprising administering an agent, which is an NMDAR agonist, an alanine-serine-cysteine transporter inhibitor, a D-amino acid oxidase inhibitor, a glycine transport inhibitor or a combination thereof to said subject.